Editor’s presentation

Abstract

The differential effect of treatment on cardiovascular risk factor levels and outcomes according to ethnicity has been suggested previously. This finding has been confirmed in a sub-analysis of the HOPE-3 trial. The results in the study population, stratified according to Asian and non-Asian ethnicity, showed several striking features: first, decreases in both blood pressure and low-density lipoprotein cholesterol levels were lower among Asians. Second, despite similar benefits regarding the reduction of both co-primary endpoints, the reduction was stronger for strokes in Asians and for myocardial infarction in non-Asians. Third, treatment by rosuvastatin increased the risk of incident diabetes in non-Asians only.